

DAFTAR PUSTAKA

- Ahjel, S. W. & Lupuleasa, D., 2009. Enhancement of Solubility and Dissolution Rate of Different Forms of Atorvastatin Calcium in Direct Compression Tablet Formulas. s.l.:Farmacia.
- American Pharmaceutical Association, 2007. *USP 30-NF 25*. USA: The United States Pharmacopeial Convention.
- Aspelmeier, Jeff. Table of Critical Values for r. Diakses tanggal 25 juli 2013.(www.radford.edu/~jaspelme/.../Table_of_Critical_Values_for_r.pdf)
- Bekers, O., Uijtendaal, E.V., Beijnen, D.A., Bult, A., and Underberg, W.J.M., 1991. Cyclodextrin in the pharmaceutical field, *Drug Dev. and Ind. Pharm.*, Vol 17 No. 11, pp. 1503-1549
- Brewster, M. E. & Loftsson, T., 2007. Cyclodextrins as Pharmaceutical Solubilizers. *Elsevier*, pp. 645-666.
- Challa, R., Ahuja, A., Ali, J. & Khar, R., 2005. Cyclodextrins in Drug Delivery: An Updated Review. *AAPS PharmsTech*, pp. E329-E350.
- Connors, K., 2000. Complex Formation. In: *Remington: The Science and Practice of Pharmacy, 20th ed.* Philadelphia: Lippincott Williams & Wilkins, pp. 183-191.
- Del Valle, E., 2004. Cyclodextrins and Their Uses: a Review. *Process Biochemistry* 39, pp. 1033-1046.
- Depkes RI, 1995. *Farmakope Indonesia Edisi IV*. Jakarta: Departemen Kesehatan RI.
- Dusautois, C., 2009. Hydroxypropyl Betacyclodextrin, an Enabling Technology for Challenging Pharmaceutical Formulations. *roquette pharma*, p. 36.

- Food and Drug Administration, 2000. *Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System*. USA: Center for Drug Evaluation and Research.
- Gingrich, Paul. "Appendix I The F Table" diakses tanggal 25 juli2013.(uregina.ca/~gingrich/f.pdf)
- Gould, S. & Scott, R. C., 2005. 2-Hydroxypropyl- β -cyclodextrin (HP- β -CD): A toxicology review. *Food and Chemical Toxicology* 43, pp. 1451-1459.
- Halasz, A. S., 2011. Solubility as a Challenge in Drug Research and Development. In: *Solubility, Delivery and ADME Problems of Drugs and Drug-Candidates*. Dubai: Bentham Science, pp. 52-67.
- J.S., P., 2010. Inclusion Complex System a Novel Technique to Improve The Solubility and Bioavailability of Poorly Soluble Drugs: a Review. *International Journal of Pharmaceutical Sciences Review and Research*, pp. 29-34.
- Jayshree, T. et al., 2012. Effect of Hydrophilic Polymer on Solubility and Dissolution of Atorvastatin Inclusion Complex. *International Journal of Pharmaceutical and Chemical Sciences*, pp. 374-385.
- Jouyban, A., 2010. *Handbook of Solubility Data for Pharmaceuticals*. USA: CRC Press.
- Kaur, A., Sharma, N. & S.L., H., 2013. Design and Development of Ketoprofen Pharmacosomes for Oral Delivery. *Pharmacophore*, pp. 111-119.
- Kurkov, S. V. & Loftsson, T., 2013. Review: Cyclodextrins. *International Journal of Pharmaceutics*, pp. 167-180.

- Martin, A., 1993. In: *Physical Pharmacy, 4th ed.* Philadelphia: Lippincott Williams & Wilkins, pp. 46-49, 257-260, 330-332.
- Martin, A., 2011. *Farmasi Fisika & Ilmu Farmasetika, Ed. 5.* In: Diterjemahkan oleh Djajadisastra, Joshita. dan H.H., Amalia. Jakarta: EGC, pp. 423-445.
- Mosher, G. & Thompson, D. O., 2007. Complexation: Cyclodextrins. In: *Encyclopedia of Pharmaceutical Technology, 3rd ed, vol. 1.* USA: Informa Healthcare, pp. 671-696.
- Nicolescu, C., Arama, C. & Monciu, C.-M., 2010. Preparation and Characterization of Inclusion Complexes Between Repaglinide and β - Cyclodextrin, 2 - Hydroxypropyl - β - Cyclodextrin and Randomly Methylated β - Cyclodextrin. *Farmacia*, Volume 58, pp. 78-88.
- Peri, D. et al., 1994. Inclusion Complexes of Tolnaftate with β -cyclodextrin and Hydroxypropyl β -cyclodextrin. *Drug Development and Industrial Pharmacy*, pp. 1401-1410.
- Rowe, R. C., Sheskey, P. J. & Quinn, M. E., 2009. *Handbook of Pharmaceutical Excipients 6th ed.* London: Pharmaceutical Press.
- Savjani, K. T., Gajjar, A. K. & Savjani, J. K., 2012. Drug Solubility: Importance and Enhancement Techniques. *ISRN Pharm*, pp. 1-41.
- Shohin, I., Kulinich, J., Ramenskaya, G. & Vasilenko, G., 2011. Evaluation of In Vitro Equivalence for Drugs Containing BCS Class II Compound Ketoprofen. *Dissolution*, pp. 26-29.
- Sweetman, S. C., 2009. *Martindale The Complete Drug Reference, 36th ed.* London SE1 7JN, UK: Pharmaceutical Press.

- Vikesh, S., Rajashree, M., Ashok, A. & Fakkirappa V., M., 2009. Influence of β -Cyclodextrin Complexation on Ketoprofen Release from Matrix Formulation. *IJPSDR*, pp. 195-202.
- Vyas, A., Saraf, S. & Saraf, S., 2008. Cyclodextrin Based Novel Drug Delivery Systems. *Journal of Inclusion Phenomena and Macrocyclic Chemistry*, pp. 23-42.
- Wadke, D. A., Serajuddin, A. T. M. & Jacobson, H., 1989. In: *Pharmaceutical Dosage Forms: Tablets, vol. 1, 2nd ed.*. New York: Marcel Dekker, pp. 18-23, 12-18.

